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Abstract
Background: The aim of this study was to investigate the effects of chondroitin sulfate (CS) on the serum levels of
Coll2-1 in patients with knee OA.
Methods: Seventy two patients with unilateral symptomatic knee OA were involved in a post-authorization open-label
study evaluating CS (800 mg/day). The primary outcome was the % relative change in serum Coll2-1 (sColl2-1). The
secondary outcomes were the evaluation of pain (VAS) and function (Lequesne’s Index). Responders and non-responders
were classified according to OMERACT-OARSI recommendations. Finally, an original cut-off method was applied to
categorize patients and interpret individual variations in serum levels of Coll2-1.
Results: Patients showed no difference in the sColl2-1 levels at baseline. When considering responders and
non-responders from the ITT population, a significant difference was found for Coll2-1 at 3 months (p = 0.030) and
6 months (p = 0.038). A decrease in pain (VAS) and an improvement in function (LI) were recorded throughout the visits
(p < 0.01). Considering an intra-batch cut-off of 21 %, CS decreased Coll2-1 serum levels between baseline and 1-month
visit compared to the value of Coll2-1 before treatment (screening visit) which can be interpreted as a drastic reduction of
the proportion of patients with an increase of Coll2-1 over 21 % (reduction from 13 to 3 %). It also consisted in a more
important proportion of patients with a decrease in Coll2-1 (from 5 to 10 %).
Conclusion: This study proposes a new approach for the analysis and the interpretation of the individual variation in
biomarker levels and introduces the notion of metabolic responders.
Trial registration: ID ISRCTN63795830. The trial was retrospectively registered on 2 October, 2015.
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Background
Osteoarthritis (OA) is one of the most common forms of
musculoskeletal disorders. It is one of the major cause of
pain and disability in the adult population [1]. The challenge
for the last decades has not only been to find a cure for OA
but also to identify tools which could help the diagnosis and
monitoring disease progression and efficacy of therapeutic
interventions. Those tools need to be accurate for the moni-
toring of structural progression of the disease and sensitive
enough to identify early event at the molecular level.
Biomarkers are among those possible tools. A biomarker
is a characteristic that is objectively measured and evaluated
as an indicator of normal biologic or pathogenic processes,
or pharmacologic responses to a therapeutic intervention
[2]. Biomarkers are not only essential for the understanding
of pathological pathways but also for diagnosis, prognosis
and follow up as previously described by Kraus et al. [3]. In
addition, they could be valuable tool in the new era of per-
sonalized medicine.
Several biomarkers of bone, synovial membrane or
cartilage metabolism have been proposed as potential
tools for diagnosis, prognosis and monitoring of OA
treatment [4]. Most of the developed biomarkers of
cartilage degradation are epitopes located in type II
collagen, one of the most specific molecules of the
articular cartilage matrix [5, 6]. Collagen is degraded by
enzymatic and non-enzymatic mechanisms in OA [7].
Included in the native form of the parental proteins,
biomarkers are very often undetectable but when
degradation processes occur, new epitopes become
detectable and then can reflect the catabolic level
present in the affected joint. Coll2-1 is a specific
biomarker of cartilage degradation. Coll2-1 was indeed
proven to be 2.5 times more elevated in OA patients
than in healthy controls [8]. In addition it was shown to
be a specific marker of cartilage degradation and to be
correlated with the radiographic progression of OA [9].
Chondroitin sulfate (CS) is classified as a symptomatic
slow-acting drug for the treatment of OA (SYSADOA)
[10]. CS has demonstrated its effectiveness in improving
pain and function in knee OA patients with a good safety
profile [11–14]. Moreover CS was shown to be able to
interfere with the pathophysiological process of OA and
thereby to reduce the structural damage [12–17].
The aim of this study was to monitor the serum levels
of Coll2-1 as primary endpoints in knee OA patients
during a 6-month treatment with CS 800 mg/day and to
measure the clinical efficacy of the treatment (i.e. pain
and function) as secondary outcome.
Methods
Study design and patients
Unilateral symptomatic knee OA patients were recruited
at the rheumatologist office of the Poal Institute of
Rheumatology of Barcelona (Barcelona, Spain) from
October 2012 to January 2014. This prospective,
observational, post-authorization open label study (ID
ISRCTN63795830) was reviewed and approved by the
local health authorities and the institutional review
board of IDIAP (Institut d’investigatiò en Atenciò
Primaria Jordi Gol - Primary Care Research Institute)
Jordi Gol i Gurina (Barcelona, Spain). Informed consent
was obtained from all study participants. The study was
performed according to the ethical principles of the
Declaration of Helsinki and to Good Clinical Practice.
Patients responding to inclusion/exclusion criteria and
considered by the physician as requiring a 6-month treat-
ment of chondroitin sulfate (800 mg/day; Condrosan®,
Bioiberica S.A., Spain) in accordance with the daily clinical
practice were selected for the study. Serum levels of
Coll2-1 (sColl2-1) and clinical evaluation (knee pain and
functional incapacity) were monitored through five visits:
selection visit (D-30), baseline visit (D0, initiation of treat-
ment), 1-month visit, 3-month visit and 6-month visit.
The consumption of NSAIDs at anti-inflammatory
doses was not allowed during the study. The use of
acetaminophen as rescue medication was recorded
throughout the study (inclusion and exclusion criteria
are detailed below).
Inclusion criteria
– Patients of both sexes and over 40 years of age
diagnosed with unilateral symptomatic OA of the
knee who met the criteria of the American College
of Rheumatology (ACR) [18].
– Patients who were rated grade II or III on the
Kellgren and Lawrence (K&L) radiological scale [19].
– Patients with symptomatic OA with a global mean
pain in the knee >40 mm on a Visual Analogue Scale
(VAS) for pain assessment.
Exclusion criteria
– Women who were pregnant or breastfeeding.
– Patients with any form of decompensated or
uncontrolled heart disease, diagnosed with renal or
liver failure, severe infections, decompensated
asthma, or a history of either alcoholism or another
drug addiction and/or uncontrolled active
psychiatric disorder.
– Patients who were grade I or IV on K&L radiological
scale.
– Patients with bilateral symptomatic knee OA or
symptomatic and developing OA in 3 or more
joints, including the knee targeted in the study.
– Patients who have had a prosthesis replaced in the
12 months prior to inclusion.
Möller et al. BMC Musculoskeletal Disorders  (2016) 17:416 Page 2 of 7
– Concurrent joint rheumatisms (history and/or
presence of signs at the time of selection) that could
give rise to a misinterpretation of the evaluation of
efficacy against pain or interfere in the evaluation,
such as chondrocalcinosis, Paget’s disease of the
limb which is ipsilateral in relation to the affected
knee, rheumatoid arthritis, aseptic osteonecrosis,
gout, septic arthritis, ochronosis, acromegaly,
hemochromatosis, Wilson’s disease,
osteochondromatosis, seronegative
spondiloarthropathy, mixed conjunctival tissue
disease, collagen vascular disease, psoriasis,
inflammatory bowel disease.
– Participants who had a diagnosis of fibromyalgia
(either by rheumatologist diagnosis, the 1990
American College of Rheumatology (ACR) criteria
[20] or the Modified 2010 ACR (ACR) criteria [21].
– Patients who performed intense physical activity
(daily or almost daily exercise practice).
– Patients with an osteotomy in the study knee.
– Arthroscopy in the previous 3 months.
– Patients with a contraindication for the use of CS.
– Patients who have used hyaluronic acid
(intra-articular hyaluronic acid in the affected knee)
during the 26 weeks prior to inclusion.
– Patients who have received intra-articular corticoid
infiltrations in either their hips or knees in the
3 months prior to the intervention.
– Patients who had received oral corticoids in the
3 months prior to starting the study.
– Patients who had taken any of the drugs classified as
SYSADOA in the three months prior to the baseline
visit.
– Patients who had taken oral and/or topical NSAIDs
(including COXIBs) at anti-inflammatory doses
during the 30 days prior to the baseline visit.
– Patients who had used medicinal plants or
homeopathic products and analgesic creams or gels
during the week prior to inclusion.
Populations
The safety population (SEP) corresponds to all the pa-
tients treated with at least one dose of the study
medication.
The Intention-To-Treat (ITT) population includes all
the patients who met inclusion and exclusion criteria,
were treated with at least one dose of the study medica-
tion and had at least a baseline efficacy measurement,
and at least one post-treatment measurement (1 month)
for the primary efficacy variable, irrespective of their
subsequent withdrawal from the study or protocol
deviations.
The Protocol Population (PP) includes all the treated
patients who met the following criteria:
– To meet the inclusion/exclusion criteria
– To be treated with at least one dose of the study
medication
– To have consumed at least 75 % of the prescribed
medication
– To have at least one baseline efficacy measurement
and one post-treatment measurement for the
primary efficacy variable
– To not present any major protocol deviation
Responders and non-responders were classified ac-
cording to OMERACT-OARSI recommendations [22].
Biomarker assay: sColl2-1
Coll2-1 has been determined in patients’ sera using
ELISA kits according to manufacturers’ instructions
(Artialis SA, Liège, Belgium).
Evaluation of pain (VAS) and function (LI)
Mean pain during the last 24 h was measured on the
Huskisson visual analog scale (VAS) [23] and function
was evaluated through the algo-functional Lesquesne
Index (LI) [24].
Coll2-1 cut-off & physiological variability
Statistical analysis of data coming from clinical trials using
Coll2-1 as biomarker of OA and comparing patients with
or without treatment, or followed over time, commonly
analyzed the results on a group basis using mean or me-
dian. This allows the identification of a significant modifi-
cation in Coll2-1 concentration across the populations.
The intended use of Coll2-1 in clinical practice is its
use as biomarker for the follow-up of patients with OA
and the monitoring of the cartilage degradation. To this
aim, each data should be analyzed on an individual basis
and interpreted in term of modification of the cartilage
metabolism for a single individual. To reach this point,
we calculated the physiological variability of Coll2-1
concentration in serum which could not be related, for a
single individual, between two time points, to a modifi-
cation of the catabolism of the cartilage. The physio-
logical variability of sColl2-1 was assessed on 15
asymptomatic subjects (NCT02348944) wherein Coll2-1
was measured at different sampling time. The group
included ten non-menopausal women and five men
(mean age: 31.6 +/−9.7 years). Intra-day and inter-day
variability of sColl2-1 level was evaluated by collecting
serum samples at four moments of the day on two
different days:
 Sampling 1: early morning, after breakfast (~9 am)
 Sampling 2: at lunch time, before lunch (~12 am)
 Sampling 3: at lunch time, after lunch (~2 pm)
 Sampling 4: at end of a workday (~5 pm)
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Day 1 of sampling at T0 was a midweek day (Tuesday)
and Day 2 of sampling at T2 was right after the weekend
(Monday) during the summer (August and September).
Instead of absolute values, the cut-off of physiological
variability for sColl2-1 was determined in percentage
change relative to baseline. This approach has been
guided by several arguments. Indeed, Coll2-1 concentra-
tion showed a high inter-individual variability. Moreover,
the use of percentage relative to baseline allows the
comparison of different studies performed with different
versions of the assay. The variability of sColl2-1 was
determined with the following formula:
ΔsColl2‐1 %ð Þ¼ sColl2‐1 nMð ÞDay2 ‐ sColl2‐1 nMð ÞDay1½ 
 sColl2‐1 nMð ÞDay1ð Þ 100
The mean variability of Coll2-1 (ΔColl2-1) calculated
for each subjects for each sampling time was 20.7 %. An
absolute value of 21 % was chosen as a threshold above
which the modification of Coll2-1 concentration is
considered as significant and related to a modification of
cartilage metabolism. This threshold designed categories
of patients:
C: from −21 to +21 % = homeostasis; A: decrease in
Coll2-1 catabolism > 21 %; E: increase in Coll2-1
catabolism.
Statistical analysis
Two-group comparisons were performed with a Student
T-test. Multiple comparisons were performed with an
ANOVA followed by Bonferroni test. P value below 0.05
was considered statistically significant.
Two approaches were used to process missing data:
– “Last-Observation- Carried-Forward” method
(LOCF), in which the value for the last observation
was used to replace the missing piece of data. Using
this method, in the case of patients withdrawn from
the study, the last observation is treated as the final
response of the patient, irrespective of the reason for
withdrawal from the study or the value at the time
of withdrawal.
– Available Case Analysis method (ACA), which




Seventy two (72) unilateral symptomatic knee OA patients
were selected for this study: 64 patients (nine men/55
women) were included in the analysis of the SEP, 61 (eight
men/53 women) for the ITT population and 59 (eight
men/51 women) for the PP population. Two (2) patients
were excluded from the ITT population due to protocol
deviations (both patients did not meet the wash-out
period criteria for the allowed concomitant medication).
The demographic characteristics (age, weight and BMI) of
the study populations are detailed in Table 1.
Patients from the ITT population were classified as re-
sponder or non-responder according to the OMERACT-
OARSI recommendations [22]. Twenty three patients
(23; 5 men/18 women) were considered as responders
and 38 (three men/35 women) as non-responders. The
demographic characteristics of the responders and non-
responders are summarized in Table 2.
Baseline values for sColl2-1 levels and pain
Patients from either ITT or PP populations showed no
difference in the sColl2-1 levels at baseline. The levels in
Coll2-1 serum in each population were respectively
(mean +/− standard deviation) 1273.0+/−330.0 nM and
1273.0 +/− 332.0 nM. The same observation was made
with responders and non-responders with different
serum levels of biomarkers (data not shown) and pain
(data not shown) at baseline.
Primary endpoint: evolution of the serum levels of Coll2-1
(sColl2-1)
The comparison of sColl2-1 levels between screening
(D-30) and baseline visit (D0; data not shown), period
without treatment, revealed no variation in both ITT
and PP populations, meaning that there was no variation
without treatment.
When considering ITT and PP populations, no signifi-
cant difference was reported throughout the follow up
period. However, most biomarkers decreased after
1 month of treatment, though this reduction did not
reach significance.
On the other hand, when considering responders and
non-responders from the ITT population, a significant
difference was found for Coll2-1 at 3 months (p = 0.030)
and 6 months (p = 0.038) (ACA approach) (Fig. 1). A sig-
nificant difference between both groups was also identi-
fied with the LOCF approach at 3 months (p = 0.0039).
Table 1 Demographic characteristics of the study populations
Mean ± SD Median Min Max
SEP Age at selection visit (years) 59.00 ± 6.6 60.0 42 71
Weight (kg) 70.7 ± 14.1 69.0 46.0 102.0
BMI (kg/m2) 27.32 ± 4.71 26.85 18.29 38.05
ITT Age at selection visit (years) 58.9 ± 6.6 60.0 42 71
Weight (kg) 70.6 ± 14.0 70.0 46.0 102.0
BMI (kg/m2) 27.39 ± 4.71 27.05 18.29 38.05
PP Age at selection visit (years) 59.0 ± 6.7 60.0 42 71
Weight (kg) 70.5 ± 14.11 70.0 46.0 102.0
BMI (kg/m2) 27.33 ± 4.77 26.64 18.29 38.05
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Secondary endpoints: evolution of pain (VAS) and
function (LI)
A decrease in pain (VAS) and an improvement in func-
tion (LI) were recorded throughout the visits (Additional
files 1 and 2). Using either LOCF or ACA approach, the
decrease in pain was significant at 1, 3 and 6 months in
ITT and PP populations when compared to baseline.
The improvement of function was shown to be signifi-
cant but to a lesser extent. Indeed significance was
reached at the 6-month visit.
Coll2-1 cut-off & physiological variability: results
Considering the categories described in Methods section
“Coll2-1 cut-off & physiological variability”, the decrease
of the Coll2-1 serum levels between baseline and the
1-month visit compared to the value of Coll2-1 before
treatment (screening visit) can be interpreted as a drastic
reduction of the proportion of patients considered as
progressors in category E (reduction from 13 to 3 %;
Table 3). Interestingly it also consisted in a more import-
ant proportion of patients with a decrease in Coll2-1 in
category A (5 to 10 %). After 3 months of treatment, the
percentage in category A (decrease in Coll2-1 catabol-
ism >21 %) still increased from 10 to 20 %. However, the
proportion of patient in category E, related to an
increase in Coll2-1 catabolism, was also increased from
3 to 20 %. This was balanced by a reduction of patients
included in the category C corresponding to physio-
logical variability.
Discussion
Biomarkers are part of the challenge in OA research for
the last decades. They have been proposed to monitor
drug efficacy [3]. Their use in clinical trial is highly
recommended [25] for their qualification. The other
challenge in OA is to find a cure that could not only
reduce symptoms (i.e. pain and function) but also
improve structure.
CS efficacy was proven on OA symptoms in various
clinical trials [11–14, 26]. The results of the present
study are in the line of these previous trials. They are
also in accordance with the SYSADOA definition [27].
Indeed the symptomatic effects are more pronounced
after a several weeks of treatment. More recently CS was
also shown to produce structural effect on the knee [17].
The structural benefit observed with MRI is partially the
consequence of molecular events which occurred earlier
in the joint tissues. Specific biomarkers could lead to an
earlier detection of those effects, traducing a metabolic
effect of the drug. The difference observed between
responders and non-responders in Coll2-1 levels could
illustrate this type of effect on the degradative event.
Biomarkers can be categorized according to the OA
process targeted as markers of cartilage degradation/syn-
thesis, bone remodeling, synovial tissue degradation/activ-
ity. The BIPEDS [3] classifies the major types of
biomarkers according their clinical information into six
categories corresponding to burden of disease, investiga-
tional, prognostic, efficacy of intervention, diagnostic bio-
markers and safety biomarkers. In 2011, OARSI/FDA
Osteoarthritis Biomarkers Working Group has classi-
fied biomarkers into four categories (exploration,
Table 2 Demographic characteristics of the responder and








Age at selection visit (years) 58.00 ± 7.26 59.50 ± 6.31 0.421
Weight (kg) 69.0 ± 13.2 71.6 ± 14.5 0.492
BMI (kg/m2) 26.80 ± 3.4 27.8 ± 5.4 0.452
Fig. 1 Serum levels of Coll2-1 in CS responder and non-responder knee OA patients
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demonstration, characterization and surrogacy levels)
according to their current level of qualification for drug
development [3, 28].
The qualification of a biomarker as a surrogate
endpoint in clinical trial is paramount. The strategy is to
correlate the variation of biomarker levels with clinical
or imaging outcomes. However, a variation of soluble
biomarker may also simply reflect a variation in tissue
metabolism. Once could consider a reduction of cartil-
age catabolism as a therapeutic target. Therefore, based
on the present results, one may wonder how to analyze
and interpret the variation in biomarkers levels.
Coll2-1 was already shown to be reduced after a
treatment, especially other SYSADOA [29, 30]. The
sensitivity and accuracy of this biomarker have already
been demonstrated. However, is it impossible to
standardize the levels and variations of such biomarker in
a disease as diversified as OA. Amidst the standard statis-
tical analysis, the cutoff approach could be a solution. In-
deed, the classification of patients in categories based not
only on the assay performance but also on patient demo-
graphic characteristics for example could yield to a better
analysis and to an illustration of the variation in the levels
of biomarkers. Herein, we demonstrate that CS might
modulate the ratio of “metabolic” responders. Further-
more we have observed that a ratio of patients showed an
increase of serum Coll2-1 levels. It could be explained by
contribution from other joints or by an increase of phys-
ical activity related to pain reduction. In addition to struc-
tural and functional responder, the notion of metabolic
responder is introduced.
Conclusions
Biomarkers are important tools for the monitoring of OA
disease and of treatment. Herein, we demonstrate that CS
may down-regulate cartilage catabolism in some but not all
patients introducing the concept of “metabolic” responders.
This study jeopardized the analysis and interpretation of
the variation in biomarker levels. This analysis of biomarker
variation should yield to an individual approach of patient
follow up. Biomarkers should provide dynamic, metabolic
and individual kinetic information.
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